Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The optimal target hemoglobin.

E Ritz1, V Schwenger

  • 1Department of Internal Medicine, Ruperto Carola University, Heidelberg, Germany.

Seminars in Nephrology
|August 6, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De novo glomerulonephritis in patients during remission from Wegener's granulomatosis.

Clinical nephrology·1992
Same author

Reduced capillary density in the myocardium of uremic rats--a stereological study.

Kidney international·1992
Same author

Renal histology in polycystic kidney disease with incipient and advanced renal failure.

Kidney international·1992
Same author

The effect of uninephrectomy on progression of renal failure in autosomal dominant polycystic kidney disease.

Journal of the American Society of Nephrology : JASN·1992
Same author

Severe hemorrhagic complications from infection with nephropathia epidemica strain of Hantavirus.

Clinical nephrology·1992
Same author

Disturbed calcium metabolism in renal failure--pathogenesis and therapeutic strategies.

Kidney international. Supplement·1992
Same journal

Current Options for Kidney Protection: Are Renin-Angiotensin System Inhibitors Still Relevant?

Seminars in nephrology·2026
Same journal

Proposed Role for Quantitative Podocyturia as a Clinical Marker of Systemic Endothelial Injury: Implications for Cardiovascular Disease and Longevity.

Seminars in nephrology·2026
Same journal

Kidney Protection Options in 2025: Are Renin-Angiotensin System Inhibitors Still Needed?

Seminars in nephrology·2026
Same journal

From Nephron Number to Global Health.

Seminars in nephrology·2026
Same journal

Chronic Kidney Disease Progression Mechanisms: Why They Matter in an Era of Novel Kidney Protective Therapies.

Seminars in nephrology·2026
Same journal

Of Diuretics, Transporters, and Mechanisms of Hypertension.

Seminars in nephrology·2026
See all related articles

Higher hemoglobin levels with recombinant human erythropoietin (rHuEPO) may improve patient outcomes. However, benefits are uncertain in patients with advanced cardiac disease, though some studies show no adverse cardiovascular effects.

Area of Science:

  • Nephrology
  • Cardiology
  • Hematology

Background:

  • The optimal target hemoglobin during recombinant human erythropoietin (rHuEPO) therapy remains debated.
  • Existing guidelines from the National Kidney Foundation Dialysis Outcomes Quality Initiative Anemia Work Group suggest specific hemoglobin targets.
  • Conflicting evidence exists regarding the benefits and risks of higher hemoglobin concentrations.

Purpose of the Study:

  • To evaluate the impact of higher hemoglobin targets during rHuEPO treatment.
  • To assess potential improvements in cognitive function, physical performance, and quality of life.
  • To investigate cardiovascular safety and effects on cardiac geometry.

Main Methods:

  • Review of existing evidence, including controlled trials and preliminary observations.

Related Experiment Videos

  • Analysis of studies examining hemoglobin normalization in patients undergoing dialysis.
  • Assessment of outcomes such as cognitive function, physical performance, quality of life, and cardiovascular events.

    • Main Results:

    • One controlled trial showed no benefit in normalizing hemoglobin in patients with advanced cardiac disease.
    • Preliminary studies suggest no adverse cardiovascular effects from normalization.
    • These studies indicated benefits in quality of life, physical performance, and cardiac geometry in some patient groups.

    Conclusions:

    • Hemoglobin concentrations higher than currently recommended may be beneficial for patients without advanced cardiac disease.
    • Further research is needed to clarify optimal hemoglobin targets in diverse patient populations, especially those with cardiac conditions.
    • Normalization of hemoglobin may offer advantages in non-cardiac patients undergoing rHuEPO therapy.